# Safety and Efficacy Study of TAR-0520 Gel in Prevention of Taxane-induced Peripheral Neuropathy

> **NCT07082764** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tarian Pharma** · enrollment: 30 (estimated)

## Conditions studied

- Chemotherapy Induced Peripheral Neuropathy

## Interventions

- **DRUG:** Brimonidine gel
- **OTHER:** No intervantion

## Key facts

- **NCT ID:** NCT07082764
- **Lead sponsor:** Tarian Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-12-15
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07082764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07082764, "Safety and Efficacy Study of TAR-0520 Gel in Prevention of Taxane-induced Peripheral Neuropathy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07082764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*